Gene expression signatures in biopsy cores as predictors of coexisting higher-grade disease in Gleason group 1 prostate cancer: Results from the Miami MAST prospective clinical trial. This is an ASCO ...

Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients ...

Heterogeneity in subgroup reporting across clinical trials assessing systemic therapies in metastatic castration resistant prostate cancer: A report from a living systematic review. Final overall ...

Van Andel Institute researchers discovered that cancer risk may be determined before birth due to distinct epigenetic states ...

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their ...

Age is the strongest risk factor, followed by ethnicity. Prostate cancer is extremely heterogeneous in its clinical behavior, ranging from indolent disease to aggressive, metastatic cancer with rapid ...

To interrogate the evolutionary origins of prostate cancer heterogeneity, we analyzed 666 prostate tumor whole genomes. We identified a compendium of 223 recurrently mutated driver regions, most ...